Last reviewed · How we verify
NCT05466370: PRETRACO
Prediction of Transfusion-Associated Complications
trial testing Transfusion of Allogeneic Blood in Transfusion-dependent Anemia in 3,366 participants. Completed in 31 July 2022.
31 July 2022
Quick facts
| Lead sponsor | Kepler University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,366 |
| Start date | 15 July 2022 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 July 2022 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Transfusion of Allogeneic Blood — full drug profile →
Conditions studied
- Transfusion-dependent Anemia — all drugs for Transfusion-dependent Anemia →
Sponsor
Kepler University Hospital
Who can join
18 and older, any sex, with Transfusion-dependent Anemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, about 350000 red blood cell concentrates are produced from blood donations in Austria every year. In addition to the main effect of replacing lost blood, red blood cell concentrates also have many undesirable effects - from blood group compatibilities, which are easily avoidable due to care, to storage-related side effects, to mostly intensive care problems as a result of massive transfusions, to system-wide effects such as TRALI, TACO and TRIM. Before being administered to patients, red blood cell concentrates undergo an extensive quality assurance process in which a large number of parameters are collected. Prior to use on patients, for example, bedside tests and tests for further incompatibilities with a blood sample from the intended patient are performed. With the implementation of Patient Blood Management (PBM) in recent years, the use of red cell concentrates has become more targeted - the number of transfusions is decreasing in most developed countries. However, it is still possible to suffer transfusion-related adverse events (TRAE). Thus, active research activity to reduce these TRAEs continues to be called for. To date, however, it is not known which patients experience transfusion-related adverse events. Despite the broad measures of hemovigilance and pre-transfusion testing, it is still not possible to predict which individual patient will respond to a transfusion with a typical adverse event such as hypotension, hemolysis, renal failure, or TRALI. It seems understandable that characteristics of the patient as well as characteristics of the administered unit could play a role for this. In particular, it is conceivable that a combination of characteristics of the blood unit and characteristics of the patient could determine a complication in the course of administration. For this reason, it seems attractive to use artificial intelligence and machine learning methods to predict any complications.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Potential Predictors for Deterioration of Renal Function After Transfusion.
Tschoellitsch T, Moser P, Maletzky A, Seidl P, et al · · 2024 · cited 2× · PMID 38364244 · DOI 10.1213/ane.0000000000006720
Verify or expand the search:
- PubMed search for NCT05466370
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transfusion-dependent Anemia
Currently open trials in the same condition.
- NCT06414031 — Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery · Phase 3 · recruiting
- NCT05924100 — Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant t · Phase 2 · recruiting
- NCT03369210 — Liberal Transfusion Strategy in Elderly Patients · Phase 3 · active not recruiting
Other Kepler University Hospital trials
Trials by the same sponsor.
- NCT06030986 — Prediction of Outcome in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT06574906 — Machine Learning Prediction of Parameters of Early Warning Scores in General Wards · active not recruiting
- NCT07506005 — Anastomotic Bleeding in Colorectal Anastomosis Relating to the Placement of the Stapler Spike to the Staple Line · recruiting
- NCT06259812 — Machine Learning Prediction of Parameters of Early Warning Scores in Intensive Care Units · active not recruiting
- NCT05753995 — Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05466370 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kepler University Hospital
- Last refreshed: 26 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05466370.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing